1-9 of 9
Morten Mau-Sørensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S. Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E. Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2693–2701.
https://doi.org/10.1158/1078-0432.CCR-23-3567
Published: 01 July 2024
View article titled, Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Open the PDF for Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek M.E. Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Tamir, Leah Henegar, Yao Shen, Mariano J. Alvarez, Andrea Califano, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, Morten Mau-Sørensen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 452–460.
https://doi.org/10.1158/1078-0432.CCR-21-2225
Published: 01 February 2022
View article titled, A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Open the PDF for A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

Dan Høgdall, Colm J. O'Rourke, Christian Dehlendorff, Ole F. Larsen, Lars H. Jensen, Astrid Z. Johansen, Hien Dang, Valentina M. Factor, Mie Grunnet, Morten Mau-Sørensen, Douglas V.N.P. Oliveira, Dorte Linnemann, Mogens K. Boisen, Xin W. Wang, Julia S. Johansen, Jesper B. Andersen
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5655–5667.
https://doi.org/10.1158/1078-0432.CCR-19-2700
Published: 02 November 2020
View article titled, Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Open the PDF for Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers in another window
Includes: Supplementary data
Journal Articles

Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (4): 1239–1247.
https://doi.org/10.1158/1078-0432.CCR-18-1780
Published: 15 February 2019
View article titled, Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Open the PDF for Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Didier Meulendijks, Wolfgang Jacob, Emile E. Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Alvaro Taus, Tania Fleitas, Andres Cervantes, Martijn P. Lolkema, Marlies H.G. Langenberg, Maja J. De Jonge, Stefan Sleijfer, Ji-Youn Han, Antonio Calles, Enriqueta Felip, Sang-We Kim, Jan H.M. Schellens, Sabine Wilson, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Suzana Vega-Harring, Rajiv Dua, Maitram Nguyen, Lori Steiner, Celine Adessi, Francesca Michielin, Birgit Bossenmaier, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5406–5415.
https://doi.org/10.1158/1078-0432.CCR-17-0812
Published: 14 September 2017
View article titled, Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Open the PDF for Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity in another window
Includes: Supplementary data
Journal Articles

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino, John A. Martignetti
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1552–1563.
https://doi.org/10.1158/1078-0432.CCR-16-1333
Published: 14 March 2017
View article titled, Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Open the PDF for Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

Didier Meulendijks, Ulrik N. Lassen, Lillian L. Siu, Alwin D.R. Huitema, Vaios Karanikas, Morten Mau-Sorensen, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Karen Wang, Mark DeMario, Glenwood D. Goss, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 858–867.
https://doi.org/10.1158/1078-0432.CCR-15-1506
Published: 14 February 2016
View article titled, Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Open the PDF for Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors in another window
Journal Articles

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Markus Hansson, Peter Gimsing, Ashraf Badros, Titti Martinsson Niskanen, Hareth Nahi, Fritz Offner, Morten Salomo, Elisabeth Sonesson, Morten Mau-Sorensen, Yvonne Stenberg, Annika Sundberg, Ingrid Teige, Jan Van Droogenbroeck, Stina Wichert, Maurizio Zangari, Björn Frendeus, Magnus Korsgren, Martine Poelman, Guido Tricot
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (12): 2730–2736.
https://doi.org/10.1158/1078-0432.CCR-14-3090
Published: 14 June 2015
View article titled, A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

Ulrik N. Lassen, Didier Meulendijks, Lilian L. Siu, Vaios Karanikas, Morten Mau-Sorensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Ka Wang, Mark DeMario, Glenwood D. Goss
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 258–266.
https://doi.org/10.1158/1078-0432.CCR-14-1334
Published: 14 January 2015
View article titled, A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
Open the PDF for A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers in another window
Includes: Supplementary data